Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.56 |
| ▸ | XIAP | P98170 | 9/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225224 | 0.87 | NOTUM (0.57) | NOTUMXIAPBIRC2LMNAPKM | |
| SCHEMBL13733355 | 0.85 | NOTUM (0.55) | NOTUMXIAPBIRC2LMNAPKM | |
| SCHEMBL2357248 | 0.84 | NOTUM (0.54) | NOTUMXIAPBIRC2LMNAPKM | |
| SCHEMBL27947018 | 0.82 | NOTUM (0.51) | NOTUMXIAPBIRC2LMNAPKM | |
| SCHEMBL430124 | 0.78 | NOTUM (0.64) | NOTUMXIAPBIRC2LMNAKMT2A | |
| SCHEMBL9687259 | 0.78 | NOTUM (0.64) | NOTUMXIAPBIRC2LMNAALDH1A1 | |
| SCHEMBL1035499 | 0.77 | NOTUM (0.59) | NOTUMXIAPBIRC2AMPD2CNR2 | |
| SCHEMBL17446878 | 0.77 | NOTUM (0.62) | NOTUMXIAPBIRC2AMPD2CNR2 | |
| SCHEMBL31481087 | 0.77 | NOTUM (0.62) | NOTUMXIAPBIRC2AMPD2CNR2 | |
| SCHEMBL31481108 | 0.77 | NOTUM (0.62) | NOTUMXIAPBIRC2AMPD2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | NOTUM 2646/4885XIAP 871/4885BIRC2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.